FindHealthNews Index  |  Save/Exchange Information |  WikiWax

    News, Reviews, and Articles on Pharmaceutical products

    Archives: Pharmaceutical products

    BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent  Jan 7, 2009
    We look forward to the first interim analysis of the ASPEN trial data which is expected to occur later in this quarter," continued Dr. Gillespie. Overview of Deal Terms Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million upfront, up to approximately $92.5 million related to clinical... (PR Newswire)

    Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings  Jan 6, 2009
    NEW YORK, Jan. 5, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: ), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 Third Quarter financial results before the U.S. stock market opens on Tuesday, January 20, 2009 ... These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and... (PR Newswire)

    Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals  Jan 6, 2009
    The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, anesthesiology, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at. (PR Newswire)

    Braille's birthday  Jan 6, 2009
    Although I currently use a computer with a voice output screen reader for my writing and correspondence, I still use Braille to maintain my telephone book, to take notes when I am traveling, to mark my clothing and pharmaceutical products and to balance my checking account. The idea that technological advancements will eliminate the need for Braille is as faulty as the notion that such developments will eliminate sighted students' need to learn to read. (Fresno Bee -- Opinion)

    New Drug Application Submitted For Acurox(r) Tablets  Jan 2, 2009
    King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience, hospital and acute care. King is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food... (Primezone Releases)

    Celgene Warns That Anticlot Drug Linked to Deaths  Jan 1, 2009
    Celgene, based in Summit, N.J., one of the country's biggest biotech companies, sells Innohep, but it is manufactured by Leo Pharmaceutical Products of Denmark, according to the product's package insert. Innohep has been sold in Europe since 1991 and was approved for U.S. sales in 2000. (ABC News -- Wire)

    Mass. gets $4.7m in drug settlement  Dec 31, 2008
    7 million payment to settle allegations of off-label marketing of three pharmaceutical products. Under terms of the settlement, the money will be paid to the Massachusetts Medicaid Program, also known as MassHealth, which provides healthcare products and services to low-income residents and those with disabilities. (Boston Globe)

    Drugmaker Pays $2.6 Million Over Off-Label Marketing  Dec 31, 2008
    6 million to the state to settle allegations of off-label marketing of three pharmaceutical products. The settlement resolves allegations that Cephalon marketed drugs for uses not approved by the Federal Drug Administration. (Law.com)

    Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)  Dec 30, 2008
    Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. (PR Newswire)

    Pegloticase BLA Filing Accepted for Priority Review by FDA  Dec 30, 2008
    Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. (PR Newswire)

    KV suspends tablet shipments, recalls drug  Dec 27, 2008
    -based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products. kvolkmann@bizjournals. (St. Louis Business Journal, MO)

    FDA approves Cumberland's new labeling  Dec 27, 2008
    Nashville-based Cumberland Pharmaceuticals is a specialty pharmaceuticals company that acquires currently marketed and late-stage development pharmaceutical products and develops them through physician segments including critical care, emergency medicine and gastroenterology. Reader Comments. (Nashville Business Journal, TN)

    Pharmaceutical industry maintains strong growth  Dec 27, 2008
    She adds that the growing awareness about medical tourism in Malaysia will attract more foreign patients to seek treatment here, and this will drive demand for pharmaceutical products ... According to the Malaysian Industrial Development Authority, Malaysias exports of pharmaceutical products have received a boost since its admission as a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation/Scheme (PIC/S) in 2002 ... She notes that the countrys... (The Star Online, Malaysia -- Business)

    Need to know: 2008  Dec 27, 2008
    US policy: In the US presidential election, Barack Obama declared in favour of healthcare reform in America, the world s biggest market for pharmaceutical products. President-elect Obama this month named Tom Baschle, the former Senate majority leader, to be Health Secretary and to oversee a new Office of Health Reform. (New York Post -- Business)

    China Biopharma, Inc. Issues Corporate Information Update  Dec 26, 2008
    Through its operating subsidiaries, the company introduces and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include biopharmaceutical and other pharmaceutical drugs. (PR Newswire)

    Nigeria bans teething drug after 25 children die  Dec 26, 2008
    Pharmaceutical products that are available by prescription only in many other countries, like anti-depressants, can often be obtained over the counter. Last year, the food and drug agency ordered the disposal of counterfeit products found to contain the toxic ingredient, diethylene glycol. (Yahoo News -- Pharmaceutical Industry News)

    To Implement the Dominican Republic-Central America-United States Free Trade Agreement with Respect to Costa Rica and for Other Purposes  Dec 26, 2008
    In Proclamation 8095 of December 29, 2006, consistent with the authority set out in section 111(b) of the Uruguay Round Agreements Act (19 U.S.C. 3521(b)), I modified the Harmonized Tariff Schedule of the United States (HTS) to implement the multilateral agreement negotiated under the auspices of the World Trade Organization to eliminate tariffs on certain pharmaceutical products and chemical intermediates ... (2) In order to make technical corrections necessary to provide the intended duty... (White House News Releases)

    Kiwis nail a Mr Big of the spam world  Dec 26, 2008
    These emails marketed Herbal King, Elite Herbal and Express Herbal branded pharmaceutical products, manufactured and shipped by Tulip Lab of India. The Department of Internal Affairs said in a statement released today that Atkinson had sought settlement of the New Zealand charges soon after the announced court proceedings against him in October. (Sydney Morning Herald -- Technology)

    Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule  Dec 25, 2008
    The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the... (PR Newswire)

    SemBioSys receives US$2.5 million in option agreement with MannKind for plant-produced insulin  Dec 25, 2008
    In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at. (PR Newswire)

    Pharma sector in good health in 2008  Dec 25, 2008
    The then Finance Minister P Chidambaram halved the excise duty on pharmaceutical products from 16 per cent to eight per cent in the Budget. To read business stories in. (India Times)

    Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge  Dec 23, 2008
    Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the U.S. WCRX-G. ... The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these... (PR Newswire)

    Kiwis nail a Mr Big of the spam world  Dec 22, 2008
    These emails marketed Herbal King, Elite Herbal and Express Herbal branded pharmaceutical products, manufactured and shipped by Tulip Lab of India. The Department of Internal Affairs said in a statement released today that Atkinson had sought settlement of the New Zealand charges soon after the announced court proceedings against him in October. (The Age)

    Prostrakan and Paladin Complete Agreement for Abstral(R) and Sancuso(R)  Dec 22, 2008
    Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)

    Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq  Dec 20, 2008
    Anesiva, Inc. seeks to be a leader in the development of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. (PR Newswire)

    FDA clears Covidien surgical system  Dec 20, 2008
    and Pharmaceutical Products division of Bermuda-based Covidien Ltd. (NYSE: COV) is based in the St. Louis area. The company is embarking on a $100 million expansion of its St. Louis County facilities over the next five years. (St. Louis Business Journal, MO)

    DSM Biologics and Crucell Announce PER.C6(R) Research License Agreement with GlaxoSmithKline  Dec 18, 2008
    DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: ; Swiss Exchange: CRX), today announced that GlaxoSmithKline (GSK) signed a license agreement allowing GSK to research a recombinant protein on the PER.C6(R) platform ... Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies ... DSM... (PR Newswire)

    Companies land Third Frontier dollars  Dec 17, 2008
    An expansion, the state said, would help take the company beyond the pilot stage with specialty chemicals and pharmaceutical products to full-scale manufacturing. The two-phase project, which would involve multimillion-dollar investments in building improvements and equipment, could create 40 new jobs through 2012. (Columbus Business First, OH)

    QLT announces interim results of radical study evaluating Visudyne combination therapy  Dec 16, 2008
    Based on the six-month data review for Visudyne combination therapy and the DSMC's recommendation, the study will continue as planned (Canada Newswire)

    Paladin Labs Announces Automatic Share Purchase Plan  Dec 15, 2008
    Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)

    Warner Chilcott to Join the Nasdaq-100 Index(R)  Dec 15, 2008
    The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to... (Primezone Releases)

    NASDAQ Announces the Annual Re-Ranking of the NASDAQ-100 Index  Dec 13, 2008
    The Company is focused on marketing, selling, developing and manufacturing branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. The St. David's, Bermuda, company had a market capitalization of $3. (Primezone Releases)

    About 1 in 9 US kids use alternative medicine  Dec 12, 2008
    Medical doctors need to be careful about attacking alternative medicine, because some long-endorsed pharmaceutical products have turned out to be treatment failures, noted Dr. Kathi Kemper, a pediatrician at the Wake Forest University School of Medicine. For example, drug makers in October announced they no longer would recommend cough and cold medicines for youngsters under 4, acknowledging there is scant evidence they work in children and that they may even be dangerous in some cases. (Chippewa Falls Chippewa Herald, WI)

    Morgan Lewis Adds Ballard Spahr Products Liability Leader  Dec 10, 2008
    The case would determine whether FDA approval of a drug serves as federal pre-emption of state law claims, having the potential to dry up a lot of the work on both the plaintiff and defense sides of pharmaceutical products liability cases. There is talk, however, of the new administration coming in and reversing via legislation any court ruling that would curb those types of state law claims. (Law.com)

    Ben Venue Laboratories, Inc. Named Recipient of the Governor's Award for Outstanding Achievement in Environmental Stewardship  Dec 9, 2008
    Each day, employees work to fulfill the company mission to provide their customers with pharmaceutical products that improve people's health and quality of life. This commitment to others also stems deeply into how the organization gives back to the community through many avenues including responsible environmental stewardship. (PR Newswire)

    Warner Chilcott Announces Receipt of Paragraph IV Certification Notices  Dec 9, 2008
    The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and... (PR Newswire)

    Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy  Dec 7, 2008
    Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at. (PR Newswire)

    Farmers have to deal with stress, too, says Charles  Dec 7, 2008
    Stress now has its own line of pharmaceutical products. She added there are two signs of too much stress. (Agri-View, WI)

    How green is this medicine?  Dec 7, 2008
    The IPC sets strict standards for drugs and other pharmaceutical products. Add to this, the wording of the amended Drugs and Cosmetics Act, which allows "only natural colouring agents as permitted under rule 26 of Prevention of Food Adulteration Rules 1955 for ayurveda, siddha and unani drugs.". (India Times, India)

    EDIF revamps Ayensu Starch Factory  Dec 6, 2008
    Mr Bonsu said there was a global requirement for starch for the production of pharmaceutical products, beverages, floor tiles, paper and spices. Source:GNA. (Ghana Web, Ghana)

    Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products  Dec 6, 2008
    Possible over-the-counter Pharmaceutical Products: a) Non-Prescription Drugs (With disease specific claims) b) Nutraceuticals (No disease specific claims) 2 ... Director and Chief Science Officer, Dr. Robert Melamede, stated, "There is an enormous need for these products. Recent advances in science have opened the door to develop, produce, and commercialize a variety of effective whole plant cannabinoid-based pharmaceutical products with a wide variety of important applications. Although... (PR Newswire)

    QLT announces commencement of tender offer  Dec 5, 2008
    Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. (Canada Newswire)

    Medical Futures partners with Norgine for MOVIPREP(R) in Canada  Dec 5, 2008
    Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL(R) for the treatment of chronic constipation and faecal impaction, MOVIPREP(R) a new generation bowel cleansing preparation, KLEAN-PREP(R) for bowel preparation prior to colonoscopy, and ORAMORPH(R) for the treatment of moderate to severe pain... (Canada Newswire)

    Forest Laboratories Responds To Unsolicited Mini-Tender Offer  Dec 4, 2008
    These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings. SOURCE Forest Laboratories, Inc.. (PR Newswire)

    ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema  Dec 2, 2008
    The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. (PR Newswire)

    Protecting Patent Owners  Nov 30, 2008
    For many of us, the word "patent" evokes an image of a legal document that protects useful inventions, like machines, pharmaceutical products and manufacturing methods. Called utility patents, these patents protect the functional or technical aspects of inventions. (Forbes -- Technology)

    Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain  Nov 29, 2008
    Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind. (PR Newswire)

    Big Pharma Faces a Crackdown in Europe  Nov 29, 2008
    Europeans spend some $275 billion a year on pharmaceutical products an average of $550 for every man, woman and child. But generic medicines can cost as much as 90% less than branded drugs: total savings gained by copycat drugs entry amounted to at least $17 billion over the 2000-2007 period examined by the Commission. (Time.com)

    Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg  Nov 27, 2008
    Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. (PR Newswire)

    Tainted Baby Teething Drug Kills 25 Children in...  Nov 27, 2008
    Pharmaceutical products that are available by prescription only in many other countries, like anti-depressants, can often be obtained over the counter. Last year, the food and drug agency ordered the disposal of counterfeit products found to contain the toxic ingredient, diethylene glycol. (Fox News)

    Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company  Nov 25, 2008
    "The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin," said Dan Chicoine, Nuvo's Chairman. "Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline." Under the collaboration, fqubed... (Canada Newswire)

    Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter  Nov 25, 2008
    These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less... (PR Newswire)

    Penwest Enters Into Second Research and Development Agreement With Otsuka Pharmaceutical  Nov 25, 2008
    Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural... (Primezone Releases)

    Manhattan Pharmaceuticals Completes $1 Million Financing  Nov 25, 2008
    Other risks that may affect forward-looking information contained in this press release include, without limitation, the company's extremely limited capital resources, the possibility of being unable to obtain regulatory approval of Manhattan Pharmaceuticals, Inc.'s product candidates, the risk that the results of clinical trials may not support the company's claims, the risk that the company's product candidates may not achieve market acceptance in North America or elsewhere, the company's... (Primezone Releases)

    Doctors, teachers in China may face graft charges  Nov 25, 2008
    Under the interpretation, medical staff face being charged with commercial bribery if they receive bribes from sales agents of pharmaceutical companies and suppliers of medical equipment, or if they help promote pharmaceutical products through their prescriptions for the benefits ... Since 2006, the SPC and SPP have reportedly cracked down on commercial bribery by focusing on areas ranging from construction, land transfer, property transactions and the purchase of medical and pharmaceutical... (Xinhuanet, China)

    Escalon sells $1.1M in stock  Nov 22, 2008
    Founded in 1987, Escalon develops and markets ophthalmic diagnostic, surgical and pharmaceutical products along with vascular access devices. Reader Comments. (Philadelphia Business Journal, PA)

    Hana Biosciences Receives NASDAQ Notification  Nov 22, 2008
    Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission. (Primezone Releases)

    Cheapened and cheated: Over medicalization and its damaging effects  Nov 22, 2008
    Since the Federal Drug Administration Modernization Act of 1997, advertising pharmaceutical products to the general public has been less restricted. Between 1996 and 2000, annual spending on direct-to-consumer advertising tripled and has been growing steadily since. (The Daily Universe, UT)

    Herbal sex remedies a hazardous cocktail, experts warn  Nov 21, 2008
    One non-government organization, the Food and Drug Protection Foundation (LPHOM), has found several kinds of banned pharmaceutical products still being sold in markets and chemists. The foundation also found many jamu kiosks selling banned drugs to customers secretly. (Jakarta Post, Indonesia -- City)

    Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer  Nov 20, 2008
    As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website. (PR Newswire)

    Personalized medicine is goal of Eli Lilly  Nov 20, 2008
    The company engages in the development, manufacturing and sale of pharmaceutical products, including neuroscience products, such as Zyprexa for treatment of schizophrenia, and endocrinology products, such as Humalog and Humulin for treatment of diabetes. Large pharmaceutical companies such as Eli Lilly are facing significant challenges due to a lack of late-stage drugs that are nearing federal approval. (AZCentral -- Business)

    Patheon Provides AcuForm(TM) Technology To Its Customers Through Ongoing Partnership with Depomed(TM)  Nov 18, 2008
    Website: TORONTO, Nov. 18 /CNW/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry has relaunched its alliance with Depomed(TM) (NYSE:DEPO), a specialty pharmaceutical company focused on enhancing pharmaceutical products, as part of Patheon's commitment on providing the best development and commercialization service offerings. The partnership of Patheon Inc. and Depomed(TM) unites the company's proprietary... (Canada Newswire)

    Covidien Q4 sales grow 12%  Nov 18, 2008
    3 billion in last year s quarter, fueled by double-digit sales increases in its medical devices, pharmaceutical products and medical supplies segments ... and Pharmaceutical Products division of Bermuda-based Covidien Ltd. (NYSE: COV) is based in the St. Louis area. (St. Louis Business Journal, MO)

    KV expects $3M loss in Q2  Nov 18, 2008
    -based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products. Reader Comments. (St. Louis Business Journal, MO)

    Patheon and Senopsys Announce Alliance  Nov 17, 2008
    The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products. These products will be optimized for palatability to increase patient compliance and improve health outcomes. (Canada Newswire)

    Escalon(R) Reports First Quarter Fiscal 2009 Results  Nov 14, 2008
    " Non-GAAP Measures To supplement the Company's consolidated financial statements presented in accordance with GAAP, the Company has begun providing certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP net loss and non-GAAP loss per fully diluted share. The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These... (PR Newswire)

    KV Pharmaceutical delays Q2 filing  Nov 14, 2008
    Brentwood-based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products, including branded and generic drugs. Reader Comments. (St. Louis Business Journal, MO)

    TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA  Nov 13, 2008
    About TheraQuest TheraQuest Biosciences, Inc. () is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. (PR Newswire)

    High Temps Degrade Contact Lens Solution  Nov 13, 2008
    "Knowledge of the potential loss of antimicrobial activity of contact lens solutions and other pharmaceutical products when exposed to higher temperatures and the risk of such exposure when storing and transporting those products may help prevent such epidemics in the future," the researchers added. HealthDay. (MEDLINEplus)

    Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy  Nov 12, 2008
    These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of... (PR Newswire)

    KV Pharmaceutical to File Form 12b-25 on November 12, 2008  Nov 11, 2008
    About KV Pharmaceutical Company KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products ... Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including... (PR Newswire)

    BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update  Nov 11, 2008
    The Company's strategy includes revenue generation in the short-to-medium-term through the sale of natural health products and in the medium-to-long-term through development of a pipeline of pharmaceutical products. Revenue from collaboration agreement amounted to nil for the current quarter ($205,000 for the nine-month period), compared to $228,000 for the same period the previous year ($913,000 for the nine-month period). (PR Newswire)

    Council awards design contract for new water plant  Nov 11, 2008
    The engineering firms will design the well field and plant, looking at alternatives to treating the increasing pollution found in the nation's water from pharmaceutical products. In answer to a question from Councilman Dave Ferris on the cost to build the plant, wells and distribution lines, Mach said the final number won't be known until the design has been completed. (Sioux City Journal, IO)

    Lorus Therapeutics to Present At Rodman & Renshaw 10th Annual Healthcare Conference November 10-12, 2008  Nov 11, 2008
    TORONTO, ONTARIO--(Marketwire - Nov. 11, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that Dr. Aiping Young, President and CEO of Lorus, is invited to present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference being held at the New York Palace Hotel, New York. WHERE: New York Palace Hotel, Kennedy 1,... (CCNMatthews Press Releases)

    Lorus Successfully Completes IND-Enabling Toxicology Studies for Lead Small Molecule Anticancer Drug LOR-253  Nov 10, 2008
    TORONTO, ONTARIO--(Marketwire - Nov. 10, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor... (CCNMatthews Press Releases)

    Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST  Nov 8, 2008
    About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. (PR Newswire)

    ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets  Nov 8, 2008
    Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product... (PR Newswire)

    Health Care Spinoff Covidien Uses Diversity To Avoid Big Dip  Nov 8, 2008
    Covidien's imaging unit sells radioactive isotopes and related pharmaceutical products for disease diagnosis and treatment, as well as contrasting agents used in imaging. The firm's medical supply line includes wound-care products; operating room supplies, electrodes, needles and syringes, as well as incontinence products. (Investors Business Daily)

    Takeda Wins Appeal Ruling Blocking Teva From Generic of Heartburn Medicine  Nov 8, 2008
    The drug was sold by TAP Pharmaceutical Products Inc., a former venture between Osaka-based Takeda and. The companies split the venture, with Takeda getting Prevacid. (Bloomberg -- Japan)

    SemBioSys announces third quarter 2008 financial and operational results  Nov 7, 2008
    In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at or This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar... (Canada Newswire)

    Informex to Introduce the GreenExchange at InformexUSA  Nov 6, 2008
    D., Rctor, DSM Pharmaceutical Products, will speak on the topic of sustainability through metabolic pathway engineered bugs ... D., Rctor, DSM Pharmaceutical Products Christopher E. Gann, Chief Executive Officer, Genomatica, Inc. In Search of Green Chemistry Excellence Since 1995, dozens of green chemical products have become commercially viable in the marketplace while a countless number of chemical production processes have been modified for greener reaction conditions. (PR Newswire)

    * MEDIPHAR TAIPEI: MEDIPHAR TAIPEI professional medical exhibition and vital procurement platform  Nov 6, 2008
    These include: Italys largest producer/distributor of medical equipment and pharmaceutical products Artsana SPA Group (annual sales US$1. 8bn), South Korean medical instrument exporter/importer Samsung Coration (grossing US$9. (Taipei Times, Taiwan -- World)

    Paladin Reports Record Third Quarter 2008 Financial Results  Nov 6, 2008
    Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)

    China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results  Nov 5, 2008
    Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit. (PR Newswire)

    'Opt Out' System Could Solve Donor Organ Shortage, Says Researcher  Nov 3, 2008
    Dr Troyer says there is currently an illegal global trade in most body parts, with teeth, nails and bones being sold on the black market to be used as pharmaceutical products and skin being used to treat burns victims. Organs such as kidneys are also being sold by living donors for large sums of money, with organs from the third world sometimes being used for first world patients who are desperate for a life-saving operation. (Science Daily)

    Archives: Pharmaceutical products

    Back to FindHealthNews Home

[ Terms Of Use | Privacy | About ]
©1998-2006 SurfWax, Inc.
All rights reserved. Patents pending.



Copyright SurfWax, Inc. 2006